Clinical Research
Clinical Research
History of Our Research Center
Dr. Whitson has been involved in conducting investigational studies beginning as far back as medical school. His desire to continue an active presence in creating, finding, or enhancing the state of medical care available to people has driven this goal.
Since starting practice in Indianapolis in 1987 he, and his team of research professionals, have conducted numerous studies and trials. Those trials have resulted in many scientific publications and presentations at medical conferences, as well as a significant number of new pharmaceutical medications that have found their way to common usage as both prescription medications and over-the-counter products.
Whitson Vision Research Center
In 2019 the Michael Washburn Center for Ophthalmic Research, LLC was formally started. It is named in memory of Dr. Whitson’s son Michael who passed in 2018. The center conducts investigational trials that are designed to help improve ocular health, comfort and vision. Our center and team have become integral components of both national and international trials. We strive for excellence in the how, what, and why of the trials that are conducted.
Therefore, we are very selective in the studies and trials in which we choose to participate. The Michael Washburn Center for Ophthalmic Research LLC looks to continue the growth path and excellence that attracts physicians, companies, and prospective study participants to us. We are proud to have this center available here in central Indiana.
Participating Clinical Trials
Dry Eye Trials
A Phase 2, Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety and Tolerability of TL-925 Ophthalmic Emulsion 0.1% in Subjects with Moderate to Severe Dry Eye Disease
Telios Pharma, Inc. 2023 Closed
A Phase 3, Multi-center, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of the MELanocortin, PL9643 Ophthalmic Solution, Compared to Vehicle in Subjects with Dry Eye (MELODY-1),
Palatin Technologies, Inc. 2023-2024 Closed
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (Comet-2)
Aerie Pharmaceuticals Inc. 2022-2023 Closed
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Aldeyra Therapeutics 2021 – 2022 Closed
A Phase-3, Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Clinical Trial to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Dry Eye Disease (CYS-004)
Novaliq GmbH 2021 Closed
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (Comet-1)
Aerie Pharmaceuticals Inc. 2021 Closed
Ophthalmic Assessments of signs and Symptoms of Dry Eye in Patients Suffering from Self-Reported or Clinician-Diagnosed Dry Eye Disease
Ora, Inc. 2021 Closed
A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye Using the Controlled Adverse Environmental
ReGenTree. 2020 Closed
Blepharitis Trials
Demodex Blepharitis Longitudinal Real-World Patient Journey Study
Trinity Life Sciences Dec. 2023- Current Active
Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn 2)
Tarsus Pharmaceuticals, Inc. 2021- 2022 Closed
Extended Observational Trial to Evaluate the Long-Term Safety of TP-03 Following Acute Treatment for Demodex Blepharitis (Saturn-1 Extension)
Tarsus Pharmaceuticals, Inc. 2021 – 2022 Closed
Randomized, Controlled, Multicenter, Double-Masked, Parallel Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn-1)
Tarsus Pharmaceuticals, Inc. 2020- 2021 Closed
Surgical Trials
Clinical Investigation of the Safety and Effectiveness of FINEVISION HP Trifocal IOL
Beaver-Visitec International, Inc (BVI) 2022-2024 Closed
Presbyopia Trials
A Multicenter, Double-Masked Evaluation of the Efficacy and Safety of Aceclidine 1.75%/Brimonidine 0.08% (LNZ101) and Aceclidine 1.75% in the Treatment of Presbyopia
Lenz Therapeutics Inc. 2022 Closed